AU2011322106A1 - Compositions and methods for specific cleavage of exogenous RNA in a cell - Google Patents

Compositions and methods for specific cleavage of exogenous RNA in a cell Download PDF

Info

Publication number
AU2011322106A1
AU2011322106A1 AU2011322106A AU2011322106A AU2011322106A1 AU 2011322106 A1 AU2011322106 A1 AU 2011322106A1 AU 2011322106 A AU2011322106 A AU 2011322106A AU 2011322106 A AU2011322106 A AU 2011322106A AU 2011322106 A1 AU2011322106 A1 AU 2011322106A1
Authority
AU
Australia
Prior art keywords
sequence
rna
interest
nucleotides
exogenous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2011322106A
Other languages
English (en)
Inventor
Guy Abitbol
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NANODOC Ltd
Original Assignee
NANODOC Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NANODOC Ltd filed Critical NANODOC Ltd
Publication of AU2011322106A1 publication Critical patent/AU2011322106A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2011322106A 2010-10-28 2011-10-27 Compositions and methods for specific cleavage of exogenous RNA in a cell Abandoned AU2011322106A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/IL2010/000895 WO2012056441A1 (en) 2010-10-28 2010-10-28 Compositions and methods for specific cleavage of exogenous rna in a cell
AUPCT/IL2010/000895 2010-10-28
PCT/IL2011/000827 WO2012056449A2 (en) 2010-10-28 2011-10-27 Compositions and methods for specific cleavage of exogenous rna in a cell

Publications (1)

Publication Number Publication Date
AU2011322106A1 true AU2011322106A1 (en) 2013-05-30

Family

ID=45993240

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011322106A Abandoned AU2011322106A1 (en) 2010-10-28 2011-10-27 Compositions and methods for specific cleavage of exogenous RNA in a cell

Country Status (7)

Country Link
US (1) US20130225660A1 (https=)
EP (1) EP2632931A4 (https=)
JP (1) JP2013544510A (https=)
CN (1) CN103282372A (https=)
AU (1) AU2011322106A1 (https=)
CA (1) CA2815632A1 (https=)
WO (2) WO2012056441A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2911034T3 (es) 2006-08-08 2022-05-17 Univ Bonn Rheinische Friedrich Wilhelms Estructura y uso de oligonucleótidos 5' fosfato
WO2009141146A1 (en) 2008-05-21 2009-11-26 Gunther Hartmann 5' triphosphate oligonucleotide with blunt end and uses thereof
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
EP3436590A4 (en) * 2016-04-01 2019-12-04 National University of Singapore TRANSSPLEISSEN OF RNA (TSRNA)
DE102017103383A1 (de) * 2017-02-20 2018-08-23 aReNA-Bio GbR (vertretungsberechtigter Gesellschafter: Dr. Heribert Bohlen, 50733 Köln) System und Verfahren zur Zelltyp-spezifischen Translation von RNA-Molekülen in Eukaryoten
WO2022182697A1 (en) * 2021-02-23 2022-09-01 Board Of Regents, The University Of Texas System A novel rna-based approach to cancer treatment

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869248A (en) * 1994-03-07 1999-02-09 Yale University Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences
ATE354957T1 (de) * 1995-12-15 2006-03-15 Intronn Inc Durch trans-spaltung erhaltene therapeutische molekule
ATE362531T1 (de) * 1999-01-26 2007-06-15 Vlaams Interuniv Inst Biotech Interne ribosom eintrittstelle (ires), vektor der diesen enthaltet und dessen therapeutische verwendung
JP2005536231A (ja) * 2002-05-08 2005-12-02 イントロン，インコーポレーテッド アデノウイルスに細胞選択的複製をもたらすための、スプライセオソーム媒介型ｒｎａトランススプライシングの使用
US20030219407A1 (en) * 2002-05-15 2003-11-27 The Regents Of The University Of California RNA silencing in animals as an antiviral defense
AU2003247696A1 (en) * 2002-07-01 2004-01-19 E.I. Du Pont De Nemours And Company Method of controlling gene silencing using site-specific recombination
EP2000160A3 (en) * 2002-10-30 2009-03-11 Gambro Lundia AB Method and apparatuses for determining the efficiency of dialysis
AU2003295600A1 (en) * 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
WO2005112620A2 (en) * 2004-05-18 2005-12-01 Massachusetts Institute Of Technology A cre-lox based method for conditional rna interference
EP1799825B1 (en) * 2004-10-05 2011-06-29 The California Institute of Technology Aptamer regulated nucleic acids and uses thereof
EP1831365B1 (en) * 2004-10-08 2013-08-07 VIRxSYS Corporation Use of rna trans-splicing for antibody gene transfer and antibody polypeptide production
JP2008537551A (ja) * 2005-03-31 2008-09-18 カランド ファーマシューティカルズ， インコーポレイテッド リボヌクレオチドレダクターゼサブユニット２の阻害剤およびその使用
CN101184840A (zh) * 2005-03-31 2008-05-21 卡兰朵医药公司 核糖核苷酸还原酶亚基2的抑制剂及其用途
US20090217397A1 (en) * 2006-06-12 2009-08-27 Patrick Stern Cre-lox based gene knockdown constructs and methods of use thereof
US8158595B2 (en) * 2006-11-09 2012-04-17 California Institute Of Technology Modular aptamer-regulated ribozymes
WO2008106658A2 (en) * 2007-03-01 2008-09-04 California Institute Of Technology TRIGGERED RNAi
US8367815B2 (en) * 2007-08-28 2013-02-05 California Institute Of Technology Modular polynucleotides for ligand-controlled regulatory systems
US9029524B2 (en) * 2007-12-10 2015-05-12 California Institute Of Technology Signal activated RNA interference

Also Published As

Publication number Publication date
CA2815632A1 (en) 2012-05-03
EP2632931A2 (en) 2013-09-04
CN103282372A (zh) 2013-09-04
US20130225660A1 (en) 2013-08-29
JP2013544510A (ja) 2013-12-19
WO2012056449A2 (en) 2012-05-03
WO2012056449A3 (en) 2012-07-19
EP2632931A4 (en) 2014-06-18
WO2012056441A1 (en) 2012-05-03

Similar Documents

Publication Publication Date Title
US20130245096A1 (en) COMPOSITIONS AND METHODS FOR ACTIVATING EXPRESSION BY A SPECIFIC ENDOGENOUS miRNA
ES2969371T3 (es) Interferencia por ARN para el tratamiento de trastornos de ganancia de función
JP5986928B2 (ja) 遺伝子発現の特異的阻害のためのダイサー基質剤及び方法
CN109072235B (zh) 通过核递送crispr/cas9追踪并操纵细胞rna
Singh et al. A short antisense oligonucleotide masking a unique intronic motif prevents skipping of a critical exon in spinal muscular atrophy
CN101307085B (zh) 抑制铁调素调节蛋白的siRNA、重组慢病毒及其应用
US20130225660A1 (en) Compositions and methods for specific cleavage of exogenous rna in a cell
WO2011047318A2 (en) Supercoiled minicircle dna for gene therapy applications
KR20190129903A (ko) 압타머-조정된 RNase P 절단에 의한 유전자 발현의 조절
CN116783295A (zh) 指导rna的新型设计及其用途
CN121464217A (zh) 用于治疗KIF1A相关神经紊乱的靶向KIF1A错义突变的RNAi
EP2739738B1 (en) Use of integrase for targeted gene expression
US20130085173A1 (en) Supercoiled minicircle dna for gene therapy applications
US20240117350A1 (en) Use of mirna-485 inhibitor to regulate psd95, synaptophysin, and caspase-3 expression
US20230119699A1 (en) Diagnostic methods using sirt1 expression
WO2024201420A1 (en) Mirna-484 inhibitors and uses thereof
Meganck Engineering Elements for Improved RNA Stability
CN119604617A (zh) 无帽无尾治疗性外源性mRNA及其生产方法
WO2021181364A1 (en) Diagnostic methods using pgc-1α expression
Elmén Nucleic acid based therapeutic approaches
Curtis et al. Developing gene knockdown-replacement therapies for spinocerebellar ataxia type 7

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period